{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:43:59Z","timestamp":1787903039062,"version":"build-2784847793"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004024","name":"Jinan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.588508","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T06:14:56Z","timestamp":1602828896000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":113,"title":["Current Prevention of COVID-19: Natural Products and Herbal Medicine"],"prefix":"10.3389","volume":"11","author":[{"given":"Junqing","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junming","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-xu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"B1","unstructured":"Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) of REMDESIVIR (GS-5734TM)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jama.2020.2565","article-title":"Presumed Asymptomatic Carrier Transmission of COVID-19","volume":"323","author":"Bai","year":"2020","journal-title":"JAMA  J. Am. Med. Assoc."},{"key":"B3","unstructured":"Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults ClinicalTrials.gov2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B6","unstructured":"Inhibition of SARS-CoV 3C-like ProteaseActivity by Theaflavin\u20133,3\u2019\u2013digallate (TF3).215\n            ChenC.-N.\n            LinC. P. C.\n            HuangK.-K.\n            ChenW.-C.\n            HsiehH.-P.\n            LiangP.-H.\n          10.1093\/ecam\/neh081Evid. Based Complementary Altern. Med22005"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2020.06.11.145920","DOI":"10.1101\/2020.06.11.145920","article-title":"SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness","volume":"2020","author":"Corbett","year":"2020","journal-title":"bioRxiv"},{"key":"B8","unstructured":"CorraoS.\n          Use of Ascorbic Acid in Patients With COVID 19 - Full Text View - ClinicalTrials.gov2020"},{"key":"B9","unstructured":"CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS\u2013CoV\u20132 Vaccine Candidate2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7326\/M20-3689","article-title":"Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy","author":"del Amo","year":"2020","journal-title":"Ann. Intern. Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-017-1585-7","article-title":"The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function","volume":"17","author":"Ding","year":"2017","journal-title":"BMC Complement. Altern. Med."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21203\/RS.3.RS-25850\/V1","article-title":"Inhibition of COVID-19 RNA-Dependent RNA Polymerase by Natural Bioactive Compounds: Molecular Docking Analysis","author":"El-Aziz Abd","year":"2020","journal-title":"Preprint"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1761881","article-title":"Natural products may interfere with SARS-CoV-2 attachment to the host cell","author":"Elfiky","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B15","unstructured":"FolegattiP. M\n            EwerK. J.\n            AleyP. K.\n            AngusB.\n            BeckerS.\n            Belij-RammerstorferS.\n          A Study of a Candidate COVID-19 Vaccine (COV001) ClinicalTrials.gov2020"},{"key":"B16","unstructured":"GallelliL.\n          Escin in Patients With Covid\u201319 Infection \u2013 Full Text View \u2013 ClinicalTrials.gov2020"},{"key":"B17","doi-asserted-by":"publisher","first-page":"eabc1932","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Sci. (80 )"},{"key":"B18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Sci. (80 )"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phymed.2011.10.010","article-title":"Antiviral activity in vitro of two preparations of the herbal medicinal product Sinupret\u00ae against viruses causing respiratory infections","volume":"19","author":"Glatthaar-Saalm\u00fcller","year":"2011","journal-title":"Phytomedicine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12071997.v1","article-title":"Natural Product Compounds in Alpinia officinarum and Ginger are Potent SARS-CoV-2 Papain-like Protease Inhibitors","author":"Goswami","year":"2020","journal-title":"chemRxiv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104776","article-title":"The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good","volume":"156","author":"Gray","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1764868","article-title":"Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL pro): an in silico screening of alkaloids and terpenoids from African medicinal plants","author":"Gyebi","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B23","unstructured":"HalperinS. A.\n            LangleyJ. M.\n          Phase I\/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada - Full Text View - ClinicalTrials.gov2020"},{"key":"B24","doi-asserted-by":"publisher","first-page":"eabd0827","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"827","author":"Hansen","year":"2020","journal-title":"Sci. (80 )"},{"key":"B25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","article-title":"COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome","volume":"52","author":"Hirano","year":"2020","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.antiviral.2006.04.014","article-title":"Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction","volume":"74","author":"Ho","year":"2007","journal-title":"Antiviral Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B28","unstructured":"HorbyP.\n            LimW. S.\n            EmbersonJ. R.\n            MafhamM.\n            BellJ. L.\n            LinsellL.\n          No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY \u2014 RECOVERY Trial2020"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104939","article-title":"Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)","volume":"158","author":"Huang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","article-title":"Neutralizing nanobodies bind SARS-CoV-2 spikeRBD and block interaction with ACE2","volume":"27","author":"Huo","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B31","unstructured":"Inovio Pharmaceuticals, Inc. - INOVIO\"s COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models. 1\u201352020"},{"key":"B32","unstructured":"Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 \u2014 Preliminary Report","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"B34","unstructured":"Janssen PharmaceuticaN. V\n          A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 \u2013 Full Text View \u2013 ClinicalTrials.gov2020"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1016\/j.bmcl.2017.05.022","article-title":"Antiviral escin derivatives from the seeds of Aesculus turbinata Blume (Japanese horse chestnut)","volume":"27","author":"Kim","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B36","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ijantimicag.2018.05.003","article-title":"Safe, high-throughput screening of natural compounds of MERS-CoV entry inhibitors using a pseudovirus expressing MERS-CoV spike protein","volume":"52","author":"Kim","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2020.02.25.965582","DOI":"10.1101\/2020.02.25.965582","article-title":"Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19","author":"Ko","year":"2020","journal-title":"bioRxiv"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110316","article-title":"Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools","volume":"128","author":"Kong","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B39","unstructured":"KoshakA.\n            KoshakE.  A.\n            MobeireekA. F.\n            BadawiM. A.\n            WaliS. O.\n          Nigella Sativa in COVID-19 \u2013 Full Text View \u2013 ClinicalTrials.gov2020"},{"key":"B40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","article-title":"Longitudinal Isolation of Potent Near-GermlineSARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients","volume":"182","author":"Kreer","year":"2020","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1775704","article-title":"Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells","author":"Kumar","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1412 LP","DOI":"10.1126\/science.367.6485.1412","article-title":"Race to find COVID-19 treatments accelerates","volume":"367","author":"Kupferschmidt","year":"2020","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","first-page":"103976","DOI":"10.1016\/j.jff.2020.103976","article-title":"Effects of four bamboo derived flavonoids onadvanced glycation end products formation in vitro","volume":"71","author":"Lan","year":"2020","journal-title":"J. Funct. Foods"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00833","article-title":"A Comprehensive Strategy to Evaluate Compatible Stability of Chinese Medicine Injection and Infusion Solutions Based on Chemical Analysis and Bioactivity Assay","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13643-020-01343-4","article-title":"Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: Protocol for a systematic review and meta-Analysis","volume":"9","author":"Li","year":"2020","journal-title":"Syst. Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104850","article-title":"Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-\u03baB signaling pathway","volume":"158","author":"Ma","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.phymed.2010.09.008","article-title":"Investigation of the influence of EPs\u00ae 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses","volume":"18","author":"Michaelis","year":"2011","journal-title":"Phytomedicine"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/jphp.13002","article-title":"Virucidal, antiviral and immunomodulatory activities of \u03b2-escin and Aesculus hippocastanum extract","volume":"70","author":"Michelini","year":"2018","journal-title":"J. Pharm. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"15214","DOI":"10.1073\/pnas.1407087111","article-title":"Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein","volume":"111","author":"Mille","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2016.07.011","article-title":"Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin","volume":"133","author":"Millet","year":"2016","journal-title":"Antiviral Res."},{"key":"B54","article-title":"Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine ( mRNA-1273 ) Against Novel Coronavirus","year":"2020"},{"key":"B55","unstructured":"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID\u201319 ClinicalTrials.gov2020"},{"key":"B56","doi-asserted-by":"publisher","first-page":"9345","DOI":"10.1074\/jbc.M411122200","article-title":"Isolation and characterization of Griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp","volume":"280","author":"Mori","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.antiviral.2017.12.010","article-title":"Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses","volume":"150","author":"M\u00fcller","year":"2018","journal-title":"Antiviral Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/2020.06.30.20142570","article-title":"Phase 1\/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report Mark","author":"Mulligan","year":"2020","journal-title":"medrxiv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.30.20142570","article-title":"Final-submission v2.0 P a g e | 1 Phase 1\/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report","author":"Mulligan","year":"2020","journal-title":"medRxiv"},{"key":"B60","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.phymed.2004.10.001","article-title":"Randomized trial of a fixed combination (KanJang\u00ae) of herbal extracts containing Adhatoda vasica, Echinacea purpurea and Eleutherococcus senticosus in patients with upper respiratory tract infections","volume":"12","author":"Narimanian","year":"2005","journal-title":"Phytomedicine"},{"key":"B61","unstructured":"Plasma programme - COVID-19 research and trials - NHS Blood and Transplant"},{"key":"B62","unstructured":"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID- 19) Nanoparticle Vaccine With\/Without Matrix\u2013M Adjuvant ClinicalTrials.gov2020"},{"key":"B63","unstructured":"Oxford COVID-19 vaccine to begin phase II\/III human trials | University of Oxford"},{"key":"B64","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.drudis.2015.01.009","article-title":"An analysis of FDA-approved drugs: Natural products and their derivatives","volume":"21","author":"Patridge","year":"2016","journal-title":"Drug Discovery Today"},{"key":"B65","unstructured":"PoloR.\n            HernanM.\n          Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel - Full Text View - ClinicalTrials.gov2020"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.13.092619","article-title":"Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals","author":"Robbiani","year":"2020","journal-title":"BioRxiv"},{"key":"B67","doi-asserted-by":"publisher","first-page":"956 LP","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizingantibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jmv.26222","article-title":"SARS-CoV-2 and SARS-CoV: Virtual Screening ofPotential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12)","author":"Ruan","year":"2020","journal-title":"J. Med. Virol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104761","article-title":"Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)","volume":"156","author":"Runfeng","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"B71","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/d41587-020-00011-1","article-title":"Convalescent serum lines up as first-choice treatment for coronavirus","volume":"38","author":"Sheridan","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B72","unstructured":"Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19) - Full Text View - ClinicalTrials.gov2020"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"B74","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jpha.2020.03.009","article-title":"Structural basis of SARS-CoV-2 3CLpro andanti-COVID-19 drug discovery from medicinal plants","volume":"10","author":"Tahir ul Qamar","year":"2020","journal-title":"J. Pharm. Anal."},{"key":"B76","doi-asserted-by":"publisher","first-page":"20\u201321","DOI":"10.1016\/j.cotox.2020.04.004","article-title":"Role of Oxidative Stress in the Efficacy and Toxicity of Herbal Supplements","author":"Tao","year":"2020","journal-title":"Curr. Opin. Toxicol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"82","DOI":"10.20307\/nps.2016.22.2.82","article-title":"Compounds from a jellyfish-derived fungus Aspergillus fumigates","volume":"22","author":"Tao","year":"2016","journal-title":"Nat. Prod. Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.antiviral.2018.07.010","article-title":"The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo","volume":"157","author":"Todt","year":"2018","journal-title":"Antiviral Res."},{"key":"B79","unstructured":"Recommendations for Investigational COVID-19 Convalescent Plasma | FDA2020"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.13.093195","article-title":"ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques","author":"van Doremalen","year":"2020","journal-title":"bioRxiv"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1039\/c004698c","article-title":"The biological potential of flavones","volume":"27","author":"Verma","year":"2010","journal-title":"Nat. Prod. Rep."},{"key":"B82","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/pr8080937","article-title":"The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19","volume":"8","author":"Wang","year":"2020","journal-title":"Processes"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/carcin\/bgy063","article-title":"Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms","volume":"39","author":"Wang","year":"2018","journal-title":"Carcinogenesis"},{"key":"B86","first-page":"1","article-title":"Chapter One - Bisbenzylisoquinoline Alkaloids","volume-title":"Alkaloids: Chemistry and Biology","author":"Weber","year":"2019"},{"key":"B87","unstructured":"WHO2020"},{"key":"B88","unstructured":"Solidarity clinical trial for COVID-19 treatments2020"},{"key":"B89","doi-asserted-by":"publisher","first-page":"10012","DOI":"10.1073\/pnas.0403596101","article-title":"Small molecules targeting severe acute respiratory syndrome human coronavirus","volume":"101","author":"Wu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2020.03.30.20047365","DOI":"10.1101\/2020.03.30.20047365","article-title":"Neutralizing antibody responses to SARS-CoV-2in a COVID-19 recovered patient cohort and their implications","author":"Wu","year":"2020","journal-title":"MedRxiv"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.apsb.2020.06.002","article-title":"Bioactive natural compounds against humancoronaviruses: a review and perspective","volume":"10","author":"Xian","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2020.101165","article-title":"Traditional Chinese Medicine treatment of COVID-19","volume":"39","author":"Xu","year":"2020","journal-title":"Complement. Ther. Clin. Pract."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104820","article-title":"Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study","volume":"157","author":"Yang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.bmcl.2012.04.081","article-title":"Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13","volume":"22","author":"Yu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms15092","article-title":"Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains","volume":"8","author":"Yuan","year":"2017","journal-title":"Nat. Commun."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104882","article-title":"The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence","volume":"157","author":"Zhang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intens. Care Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1021\/acs.nanolett.0c02278","article-title":"Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity","volume":"20","author":"Zhang","year":"2020","journal-title":"Nano Lett."},{"key":"B100","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2020.03.035","article-title":"A Genomic Perspective on the Origin and Emergence of SARS-CoV-2","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"B101","unstructured":"ZhuF. C.\n            GuanX. H.\n            LiY. H.\n            HuangJ. Y.\n            JiangT.\n            HouL. H.\n          A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) ClinicalTrials.gov.2020"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","article-title":"Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein","volume":"26","author":"Zost","year":"2020","journal-title":"Nat. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.588508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T06:15:20Z","timestamp":1602828920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.588508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":103,"alternative-id":["10.3389\/fphar.2020.588508"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.588508","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"article-number":"588508"}}